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Introduction: The effects of endogenous cortisol (F) excess on bone
mass and vertebral fractures have still not been thoroughly investi-
gated. The aim of this cross-sectional case-control study was to in-
vestigate factors influencing bone demineralization and vertebral
fractures in different conditions of F excess, i.e.Cushing’s disease and
adrenal and ectopic Cushing’s syndrome.
Materials and Methods: Eighty consecutive patients and 80 con-
trols were prospectively enrolled: 37 patients (21 females) with pi-
tuitaryACTH-secreting adenoma, 18 (14 females)with adrenocortical
adenoma, 15 (11 females) with adrenal carcinoma of mixed secretion,
and 10 (three females) with ectopic ACTH secretion. The groups had
similar age. At diagnosis, bone mineral density (BMD) was deter-
mined by the dual-energy x-ray absorptiometry technique at the lum-
bar spine (L1–L4) and femoral neck; vertebral fractures were inves-
tigated by standard spinal radiographs.
Results: When comparing the groups with different etiology of F
excess, the patients with ectopic ACTH secretion had higher F and
lower BMD values than the other subgroups. Morning F (P  0.03)
and testosterone levels (P  0.04) correlated with lumbar BMD. Ver-
tebral fractures were found in 61 (76%) of the patients, were multiple
in 52 (85%) of the cases, and clinically evident in 32 (52%). Only
multiple fractures were more frequent in patients with ectopic ACTH
hypersecretion (P 0.05). Lumbar spine BMDwas the best predictor
of vertebral fractures (P  0.01). Surprisingly, amenorrheic and eu-
menorrheic women had similar BMD values and fracture prevalence.
Conclusion: A high prevalence (76%) of vertebral fracture was re-
vealed, regardless of the etiology of the patients’ hypercortisolism.
The harmful effects of F excess at the spine were partly counterbal-
anced by the increased androgen production but were not affected by
gonadal status in women. (J Clin Endocrinol Metab 91:
1779–1784, 2006)
THE SYNDROME OF glucocorticoid excess, first de-scribed in 1932 by Harvey Cushing, is recognized as
one of the most important causes of bone loss (1). Cortisol (F)
exerts direct and indirect effects on bone, enhancing its re-
sorption and inhibiting its formation (2, 3–5). Glucocorticoid
excess directly inhibits the differentiation of pluripotentmes-
enchymal cells toward the osteoblastic lineage, directing
them into the adipocytic pathway (6). It reduces the produc-
tion of growth factors and bone matrix proteins and de-
creases calcium absorption (7). Bone fractures, themain com-
plication of osteoporosis, are well recognized as a dose-
dependent effect in patients on glucocorticoid treatment and
have been described as a presenting symptomof endogenous
F excess (8, 9). A high incidence of nontraumatic fractures in
the period preceding the diagnosis of Cushing’s syndrome
was described in 104 patients in a retrospective study by
Vestergaard et al. (10).
The negative effects of F on the bone probably depend on
the degree of its excess, whereas sex steroids have anabolic
effects. The relationship between F and sex steroids may be
complex in patients with endogenous hypercortisolism. It is
well known that F excess alone inhibits the gonadal axis in
both genders (3, 5); nevertheless, the production of dehy-
droepiandrosterone sulfate (DHEAS) and androstenedione
is generally increased in ACTH-dependent hypercortisolism
and frequently high in adrenocortical carcinomas, together
with the testosterone (T) levels. Androstenedione, DHEAS,
and T are usually low in adrenal adenomas (11, 12). Estro-
gens may be increased in subjects with adrenal carcinomas
but are frequently low in women with ACTH excess and
adrenal adenomas (13, 14). Androgen excess has been found
to exert protective effects on bone mass in women with
polycystic ovary syndrome, counterbalancing the harmful
effects of amenorrhea (15, 16). With regard to the effects of
estrogens, corticosteroid treatment and Cushing’s syndrome
have been shown to cause more severe bone damage in
postmenopausal than reproductive-aged women (17, 18).
Nevertheless, it is still unclear whether any protective bone
effects of androgens or estrogens can occur in patients with
endogenous F excess. Few data are currently available on the
effects of mixed F, androgen, and estrogen excess on bone
mass and the prevalence of vertebral fractures.
This cross-sectional, case-control study aimed at investi-
gating the risk factors for bone demineralization and verte-
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bral fractures in endogenous glucocorticoid excess of differ-
ent etiologies.
Subjects and Methods
Study design
In this cross-sectional, case-control study, we have analyzed deter-
minants of bone demineralization and vertebral fractures in glucocor-
ticoid excess of different etiologies. We took into consideration the
gender, anthropomorphic features, estimated disease duration, serum F,
T, androstenedione, DHEAS, and 17--estradiol (E2) levels, and the
ratios among serum F, androgens, and E2. All determinations were
performed at the diagnosis of Cushing’s syndrome. The study was
performed according to the procedures indicated by the Helsinki II
Declaration. All enrolled subjects gave their informed consent to par-
ticipate in the study.
Subjects
From January 1996 to June 2003, 80 consecutive patients with en-
dogenous F excess were referred to our department and prospectively
enrolled in this study. The diagnosis of F excess was made on the basis
of the typical clinical signs and symptoms and inappropriately elevated
values of serum F and urinary free F (UFF) excretions. Additional in-
vestigations included assays of circulating ACTH, FSH, LH, and pro-
lactin levels, a low-dose 2-mg dexamethasone suppression test in all
cases, and a high-dose 8-mg dexamethasone suppression test in all
patients with ACTH-dependent Cushing’s syndrome; pituitary mag-
netic resonance imaging or adrenal computed tomography was
performed as appropriate. A whole-body scintigraphy with 111In-DTPA-
d-phe1-octreotidewasperformed inpatientswith suspected ectopicACTH
hypersecretion; areas of abnormal uptake were then evaluated by com-
puted tomography scan to confirm the presence of lesions. Among the 80
patients, histology confirmed the diagnosis of pituitary ACTH-secreting
adenoma in 37 (microadenoma in 30 andmacroadenoma in seven) of them,
F-secreting adrenocortical adenoma in 18,mixedF- andandrogen-secreting
adrenocortical adenoma in four, mixed secreting carcinoma in 11, and
ectopic ACTH excess due to bronchial carcinoid in eight patients. In the
remaining two patients, a diagnosis of ectopic ACTH syndrome was sus-
pected, but the tumor site is still unknown. Disease durationwas estimated
around the interval between the symptom onsetmentioned by the patients
when specifically asked (i.e. weight gain, appearance of striae rubrae, in-
crease in blood pressure, etc.) and the diagnosis. Patients were considered
to have hyperandrogenismwhen at least one of the androgens (T, DHEAS,
or androstenedione)was 2 sd above themean of the controls.Womenwere
considered amenorrheic when menstrual cycles did not occur at regular
intervals and E2 levels were below the normal range for the early follicular
phase.
For each patient enrolled, a control subject matched for age, gender,
and body mass index (BMI) was selected and included in the data
analysis. Eighty subjects with eucortisolism were recruited among the
patients with euthyroid goiter (TSH, 1–2.5 U/liter). Age was matched
within 1 yr of the birth date, and BMI was matched within1.5 kg/m2.
None of the 160 subjects had previously taken drugs known to interfere
with bone metabolism, oral contraceptive, or hormonal replacement
therapy, nor used to drink more than four cups of coffee per day and/or
two alcohol-containing beverages per day.
Assessment of bone density and turnover
Serum calcium, phosphorus, creatinine, alkaline phosphatase (ALP),
albumin, intact PTH (iPTH), and osteocalcin were determined after at
least 8 h fasting, whereas urinary calcium and hydroxyproline excretion
were measured in 24-h urine collection and corrected for creatinine
excretion. Bone mineral density (BMD) at the lumbar spine (L1–L4 in
anteroposterior scan) and femoral neck was determined by dual-energy
x-ray absorptiometry using Hologic QDR 1000 densitometer (Hologic,
Inc., Waltham, MA). Because of mixed (male and female) population,
individual BMD values were expressed as Z scores. The coefficient of
variation for the dual-energy x-ray absorptiometry technique was less
than 1.5% for the lumbar spine and less than 1.8% for the femoral neck.
The reference population adopted in this study was the international
pooled sample provided by the manufacturer; their data, however, did
not differ significantly from those obtained on a local sample in a study
performed when the device was set up (19). Quality control was main-
tained by daily scanning of an anthropomorphic spine phantom. A
systematic review of each BMD was performed, and artifacts from
fractured vertebral bodies, kyphosis, and scoliosis were excluded from
the evaluation. No patient had imbedded metal at the lumbar vertebrae
or severe joint disease at the L1–L4 segments.
Assessment of vertebral fractures
All patients were evaluated for back pain and height changes as
clinical symptoms of vertebral fractures. Potential asymptomatic ver-
tebral compression fractures were investigated in all patients by stan-
dard spinal radiographs in anterior-posterior and lateral positions of the
vertebrae Th4–L4. A prevalent fracture was defined in accordance with
previous studies, with a 20% difference in anteroposterior, middle-
posterior, or posterior-posterior adjacent ratio (20, 21). Vertebral collapse
was defined as wedge-shaped, biconcave, or completely collapsed bod-
ies (20, 21). Because most patients had a very severe demineralization of
the vertebral bodies, it was impossible to use the digitalized technique
for vertebral body measurement. An analysis of radiographic films was
independently performed in chronological order by two operators: a
skeletal radiologist (L.C.) and an endocrinologist trained in osteoporosis
management (L.T.). They were blind to the status of case/control and
origin of F excess. The validity of each finding was established by both
operators for the detection of the presence and number of fractures; the
interobserver agreement was calculated using k statistics, and results
were good (k  0.87).
Assays
Hormone determinations were performed with the same commercial
kits for the whole study period: F, T, E2, and DHEA-S by Immulite and
solid-phase chemoluminescent enzyme immunoassay (Diagnostic Prod-
ucts Corp., Los Angeles, CA); androstenedione by RIA Diagnostic Sys-
tems Laboratories (Webster, TX); FSH and LH by RIA using Biodata kits
(Rimini, Italy); and prolactin by RIA using Radim kits (Pomezia, Italy).
iPTH and serum osteocalcin levels were measured by RIA (Nichols
InstituteDiagnostics, SanClemente, CA).Hydroxyproline excretionwas
measured with HPLC. Blood chemistry profile, including levels of cal-
cium, phosphorus, ALP, 24-h urinary calcium excretion, and creatinine,
were analyzed using a standard autoanalyzer.
Statistical analysis
The statistical analysis was performed by the SPSS Inc. (Chicago, IL)
package (release 13.0) and StatsDirect statistical software (release 2.5.2,
StatsDirect Ltd., Cheshire, UK). Data distribution was analyzed by the
Kolmogorov-Smirnov test. To compare data for continuous variables,
ANOVA followed by Bonferroni test as post hoc test or Kruskal-Wallis
H test followed by Dwass-Steel-Chritchlow-Fligner test (22) were used,
according to the data distribution. Categorical variables were compared
by using the Pearson’s 2 test. The datawere compared between patients
and controls, between patients with and without fractures, and between
subgroups of patients with different etiology of F excess. Age, BMI,
estimated disease duration, urinary F excretion, and circulating levels of
F, androgens, and E2 were considered as potential predictive factors for
BMD by the linear regression analysis. All these parameters plus BMD
were included in the evaluation of risk factors for vertebral fractures by
the logistic regression. The step-wise forward selection was used for
both procedures. Predictive factors of vertebral fractures have been
evaluated by the receiver operating characteristic analysis on the dif-
ferent parameters considering the value associated with the maximal
diagnostic accuracy (maximal sum of sensitivity and specificity). Sta-
tistical significance was set at 5%.
Results
Anthropometrical and endocrine profiles (Table 1)
Age was similar in all groups of patients, whereas the
estimated disease duration was shorter in patients with ec-
topic ACTH secretion and adrenal carcinomas when com-
pared with the other subgroups (P  0.01). BMI was higher
in the patients with isolated F excess due to adrenal adenoma
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(P 0.05 vs. all other groups). Women were more frequently
affected by F excess than men in all subgroups except for the
ectopic ACTH secretion, where men were more frequently
represented. The ratio of amenorrheic vs. eumenorrheic
women in each subgroup was similar.
Higher serum and urinary F levels, serum androstenedione,
and DHEAS levels were found in ectopic and pituitary ACTH
hypersecretion than in adrenal adenomas and carcinomas. An-
drostenedione and DHEAS were lower in adrenal adenomas
than in the other subgroups (P  0.05). DHEAS and E2 were
higher in adrenal carcinomas than in the other groups (P 
0.05); E2 was similar amongmen andwomenwith carcinomas,
indicating that most adrenal malignancies produce small to
large amounts of E2. T was lower in men with Cushing’s dis-
ease, adrenal adenoma, and ectopic ACTH secretion than in
those with adrenal carcinoma (P  0.05). The latter one was
similar to controls. Women with adrenal carcinoma, pituitary,
and ectopic ACTH hypersecretion had T levels significantly
higher (P  0.05) than controls, whereas those with adrenal
adenoma had lower values (P  0.05).
Assessment of bone density and turnover (Table 2)
Calcium, phosphorus, iPTH, and vitamin D values did not
differ between controls and patients of any subgroup. Serum
osteocalcin levels were lower and hydroxyproline excretion
TABLE 2. Parameters of bone turnover, bone density, and fractures in patients and controls
Variable ACTH-secretingpituitary adenoma
Adrenal
adenoma
Adrenal
carcinoma
Ectopic
ACTH excess Controls
No. of subjects 37 18 15 10 80
Serum calcium (mmol/liter) 2.36  0.13 2.38  0.15 2.34  0.14 2.39  0.16 2.33  0.11
Albumin (g/dl) 3.99  0.44 4.06  0.36 3.86  0.5 4.28  0.3 4.1  0.3
Urinary calcium excretion
(mg/24 h)
182  95 215  88 171  44 192  62 166  73
iPTH (ng/liter) 43.4  12 40.2  14 38  15 44.5  13 41.2  16
Osteocalcin (ng/ml) 1.5  0.5a 2.3  0.7 2.4  0.9 1.2  0.4a 8.9  2.4b
ALP (U/liter) 153  52 174.5  58 185  61 187  49 168  58
Creatinine (mol/liter) 86  8.6 88  8.9 90  9 87  8.7 82  9.8
Hydroxyprolinuria (mol/m2) 135  41.5 129  36 127.5  32 137  40 102  16b
Lumbar Z score (SD) 1.97 (5.15 to 0.06) 1.8 (4 to 0.36) 1.8 (2.9 to 0.9) 3.53 (4.9 to 3.0)c 0.03  1.1d
Femoral Z score (SD) 1.04 (2.6 to 0.3) 1.5 (2.6 to 1.2) 0.8 (2.3 to 0.7) 0.6 (2.45 to 0.2) 0.05  0.8b
Prevalence (%) of any vertebral
fracture
29 (78%) 12 (67%) 10 (67%) 10 (100%) 1 (1.3%)d
Clinical fracturese 15 (52%) 6 (60%) 4 (40%) 7 (70%) 0 (0%)b
Multiple fracturese 25 (86%) 9 (75%)f 8 (80%)f 10 (100%) 0 (0%)d
Data are expressed as mean  SD or median and range, as appropriate.
a P  0.05 vs. all other groups of patients.
b P  0.05 vs. all groups of patients.
c P  0.01 vs. all other groups of patients.
d P  0.01 vs. all groups of patients.
e The percentage of clinical andmultiple fractures was calculated as a subset of patients with any fracture. Reference ranges: calcium, 2.2–2.6
mmol/liter; ALP, 98–275 U/liter; creatinine, less than 133 mol/liter; albumin, 3.6–5.2 g/dl; osteocalcin, 2–22 ng/ml; PTH, 10–75 ng/liter;
hydroxyproline excretion, 60–190 mol/m2.
f P  0.05 vs. ectopic ACTH hypersecretion.
TABLE 1. Clinical features of patients and controls
Variable ACTH-secretingpituitary adenoma
Adrenal
adenoma
Adrenal
carcinoma
Ectopic
ACTH excess Controls
No. of subjects 37 18 15 10 80
Female/male 21/16 14/4 11/4 3/7 49/31
Age (yr) 38 (18–58) 38 (22–66) 41.5 (27–58) 42 (29–52) 39 (18–66)
BMI (kg/m2) 26.9 (21–40.2) 28.3 (21.3–40.4) 28.2 (21–33) 27 (21.6–33.7) 27 (21–40)
Estimated disease
duration (months)
19 (8–26)a 21 (7–25)a 8.3 (5–13) 8.1 (4–11)
No. of amenorrheic women 9/21 (42.8%) 6/14 (42.8%) 4/11 (36.4%) 2/3 (66%) 6/49 (12%)
F 0800 h (nmol/liter) 725.6 (276–1,344)b,c 619 (544–1,173)d 560 (328–957)b 690 (469–1,724)b,c 364 (260–482)
UFF excretion (nmol/24 h) 1,504 (326–9,290)a,c 1,496 (306–4,139)d 1,847 (323–6,208)c 5,132 (1,270–14,987)b,c 423 (179–331)
DHEAS (mol/liter) 8.3 (2.6–18)b 1.6 (1.3–5.8)b,e 20 (4.3–99)b,e 9 (5.9–19.5)b 6.5 (4.3–8.4)
Androstenedione (nmol/liter) 12.2 (3.5–34.9)b 3.14 (0.34–19.2)e 27 (3.8–58)b 23 (6.8–69)b 4.0 (1–7.7)
Male T (nmol/liter) 7.7 (4.1–13)d 5.5 (3.2–7.8)b,e 18 (12–36) 9 (5–14.5)d 19.4 (12–35)
Female T (nmol/liter) 6.1 (3.2–10)b 0.9 (0.3–1.3)b,e 5 (1.4–52)d 6.8 (3.1–13)b 2.42  0.52
Female E2 (pmol/liter)
f 124 (55–191) 159 (53–716) 352 (132–1,534)be 121 (55–147) 147  18.8
Data are expressed as median and range. Reference ranges: F, 140–680 nmol/liter; UFF excretion, 55–300 nmol/24 h; DHEAS, 1.3–6.7
mol/liter; androstenedione, 3.0–6.0 nmol/liter; male T, 10–35 nmol/liter; female T, less than 3.5 nmol/liter; E2, 70–220 pmol/liter.
a P  0.01 vs. groups with adrenal carcinoma and ectopic ACTH excess.
b P  0.001 vs. controls.
c P  0.05 vs. groups with Cushing’s syndrome due to adrenal adenoma or carcinoma.
d P  0.05 vs. controls.
e P  0.05 vs. all other groups of patients.
f Determined in early follicular phase in women with cycles.
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higher in patients than controls (P  0.05). Osteocalcin was
lower in patients with pituitary and ectopic ACTH secretion
than in those with adrenal tumors (P  0.05).
Both lumbar (P 0.01) and femoral BMD (P 0.05) values
were significantly lower in patients than controls. Gender-
and age-corrected lumbar BMDwas lower in the group with
ectopic ACTH secretion (P  0.01 vs. all groups) but similar
among the others.
Assessment of vertebral fractures (Table 2)
Vertebral fractures were found in 61 (76%) patients, with
multiple involvement of thoracic and/or lumbar vertebrae in
52 (85%). Clinically symptomatic collapsed vertebrae were
found in 32 (52%) patients; they were associated with pain,
functional limitation, and height shortening by 3–10 cm of
final stature. Twenty-nine patients (48% of those with frac-
tures) had asymptomatic fractures, which were multiple in
22 (76%) of them. The fractures involved the thoracic verte-
bral bodies in 52% of patients, the lumbar vertebrae in 23%
of patients, and both thoracic and lumbar bodies in 25% of
cases. Seven patients with vertebral fractures (11%) had val-
ues of lumbar BMDwithin the normal range. The prevalence
of any and clinical fractures did not differ among the groups
with different disease etiology, whereas multiple fractures
were more frequent in patients with ectopic ACTH hyper-
secretion when compared with those with adrenal tumors
(P  0.05).
When comparing the patients with fractures with those
without fractures, the first grouphaddecreased lumbar BMD
(0.83  0.14 vs. 1.03  0.19 g/cm2; P  0.001), whereas both
groups presented similar age, BMI, and endocrine
parameters.
Predictive factors for bone loss and fractures
Lumbar and femoral BMD correlated with morning F (r
0.36, P 0.03 and r0.4, P 0.02, respectively) and total
T (r  0.35, P  0.04 and r  0.58; P  0.015, respectively),
whereas femoral BMD showed a trend alsowithDHEAS (r
0.47; P  0.06). There was no correlation between BMD and
E2 values.
By logistic regression analysis, vertebral fractures were
predicted by lumbar BMD values (  0.61; P  0.001).
Among the different parameters evaluated to distinguish
those with a predictive value, lumbar BMDwas the only one
statistically significant at receiver operating characteristic
analysis with the area under the curve of 0.87  0.07 (95%
confidence interval, 0.74–1.008; P  0.001). Lumbar BMD
value of 0.823 g/cm2 indicated the cutoff to distinguish pa-
tients with and without vertebral fractures with a sensitivity
of 100% and specificity of 53%.
Surprisingly, there were no differences in lumbar BMD Z
score (1.96  1.14 vs. 1.61  1.13; P  0.367) and prev-
alence of fractures [18 of 21 (86%) vs. 16 of 28 (57%); P 0.1]
between amenorrheic and eumenorrheicwomen. Their F and
androgen levels did not differ significantly as well as those
of E2 (191  209 vs. 261  305 pmol/liter; P  0.3).
Discussion
This is the first systematic evaluation of both symptomatic
and nonsymptomatic vertebral fractures and their risk fac-
tors in a large population of patients with endogenous F
excess. A high prevalence (76%) of vertebral fractures was
revealed, regardless of the different etiology of patients’ hy-
percortisolism. A lower lumbar BMD was a predictor for
vertebral fractures.
Patients with ectopic and pituitary ACTH hypersecretion
had more severe F excess than those with adrenal adenomas
or carcinomas. Androgen excess (high DHEAS, andro-
stenedione, and female T) was present in patients with pi-
tuitary and ectopic Cushing, whereas the excess of andro-
gens plus estrogens was revealed in patients with adrenal
carcinoma. F and total T correlated with both lumbar and
femoral BMD in our patients, whereas Minetto et al. (23)
showed a significant correlation between DHEAS and BMD
at either lumbar spine or femoral neck.
Surprisingly, serum androgens were similar in men and
women with overt Cushing’s syndrome. Moreover, in our
experience, amenorrheic and eumenorrheic women had sim-
ilar bone density and prevalence of fractures. Although their
E2 values overlapped, the lack of any relationship among E2,
BMD, and fractures in this study can likely be explained by
the negative bony effects of overt hypercortisolism, which
overwhelm the positive effects of estrogens in this particular
population. Because the decrease in estrogen levels in the
general population is the most important cause of bone loss
and the number of women included in each patient group in
this study was relatively small, some milder correlation may
have been missed. As a matter of fact, Karavitaki et al. (18)
have documented reduced forearm BMD in 16 postmeno-
pausal but not in 13 premenopausal women with Cushing’s
syndrome; nevertheless, peripheral and axial skeleton may
have different behavior during the F excess.
Our data suggested that among the risk factors considered
for bone loss, spinal bone status worsened proportionally
with the degree of F excess, being partly influenced by in-
creased androgen levels but not directly by E2.
As concerning the etiology of F excess, lower lumbar BMD
and a higher frequency of multiple fractures were observed
in patients with ectopic ACTH excess, whereas there was no
statistical difference between subjects with pituitary or ad-
renal Cushing’s disease. This is in contrast with a previous
finding byOhmori et al. (24) who reported a greater bone loss
in patients with pure F excess due to adrenal adenomas
compared with those with Cushing’s disease and attributed
this difference to the protective effect of androgens.
Concerning the fractures, the prevalence revealed by this
study is not so surprising because Chiodini et al. (25) have
recently reported a prevalence of vertebral fractures as high
as 43% in premenopausal and 78% in postmenopausal
women with subclinical hypercortisolism due to adrenal in-
cidentaloma.Male patients weremore frequently affected by
clinically evident fractures. Thoracic vertebrae were more
frequently fractured than the lumbar ones. However, there
are no data on predictive factors for fractures in endogenous
hypercortisolism. On the other hand, in patients with exog-
enous F excess, a daily dose was found to be a strong pre-
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dictor of vertebral fractures by Van Staa et al. (26), whereas
combined effects of higher doses, longer duration, and a
continuous pattern of exposure increased the relative risk for
vertebral and nonvertebral fractures in the study by Stein-
buch et al. (27). Overt endogenous F excess is likely more
severe than that caused by corticosteroid treatments because
only some of the patients on steroid therapy develop typical
symptoms of hypercortisolism.
The high prevalence of multiple vertebral fractures de-
tected in the current study at diagnosis of F excess is of
particular clinical relevance because they are irreversible. An
increase in BMD ranging from 14–79% has been reported in
patients successfully treated for endogenous F excess (28–
30), and fracture incidence decreased after glucocorticoid
treatment withdrawal (26). These findings point out the ne-
cessity of a very precocious preventive treatment to reduce,
at least partially, the detrimental effects of F excess on the
bone. In fact, the use of calcium, vitamin D, and bisphos-
phonates is recommended for the prevention of bone loss in
chronic users of corticosteroids (31, 32), and we previously
reported that bisphosphonate treatment counterbalanced the
negative effects of hypercortisolism in patients with active
Cushing’s disease (33).
Although lumbar BMDwas found to be a predictive factor
for vertebral fractures, this study confirms that patients with
either exogenous or endogenous F excess are at risk for
symptomatic and nonsymptomatic vertebral fractures even
at normal densitometric values, and a radiography of the
spine is required to assess the morphology of vertebral
bodies.
In conclusion, this study confirms and extends previous
observations on the negative early and dose-dependent ef-
fects of endogenous F excess on bone density and bone turn-
over (10, 34–36). The harmful effects of hypercortisolism on
the spine were partly counterbalanced by an increased an-
drogen production in both genders but not by female go-
nadal status. Among the groups with different etiology of F
excess, the patients with ectopic ACTH secretion had higher
F, lower lumbar BMD values, and more frequent multiple
fractures. Any vertebral fracture was present in 76% of the
patients at diagnosis of Cushing’s syndrome, regardless of its
etiology. The best preventive intervention should include a
very early diagnosis of F excess, simultaneous bone status
evaluation, and a prompt preventive treatment. Unfortu-
nately, it is not an easy task in a common clinical practice.
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